Shilpa Medicare
Drug Manufacturers - Specialty & Generic · SHILPAMED
Mid CapHealthcareMature Stable
Vishnukant Chaturbhuj Bhutada
Managing Director · Visionary
Company DNA
Innovation-Led
About
Shilpa Medicare is a Mid Cap company in the Healthcare sector, listed on NSE as SHILPAMED. With a market cap of ₹7K Cr and revenue of ₹1K Cr, it is currently in the Mature Stable phase. Known for its Innovation-Led culture and Disruptor approach to innovation, the company operates at a Steady-Marathon pace. Focus on R&D-intensive pharmaceutical manufacturing and specialty generics requires an experimentation-based, innovation-led structure. Its strategic mandate: The firm must pivot towards high-value complex generics and niche oncology portfolios to break out of current stagnant growth cycles.
FAQ
What kind of company is Shilpa Medicare?
Shilpa Medicare is a Mid Cap Healthcare company (SHILPAMED) in the Mature Stable phase with a market cap of ₹7K Cr. It is classified as Innovation-Led in culture.
What is Shilpa Medicare's culture and work environment like?
Shilpa Medicare has a Innovation-Led culture with Disruptor innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Focus on R&D-intensive pharmaceutical manufacturing and specialty generics requires an experimentation-based, innovation-led structure.
Who leads Shilpa Medicare?
Shilpa Medicare is led by Vishnukant Chaturbhuj Bhutada (Managing Director), a Visionary leader with 39 years of experience.
What are Shilpa Medicare's financials?
Shilpa Medicare reported revenue of ₹1K Cr in FY25 with a 5-year revenue CAGR of 4.1%. Operating margin: 15.6%. Market cap: ₹7K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationDisruptor
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleMature Stable
Focus on R&D-intensive pharmaceutical manufacturing and specialty generics requires an experimentation-based, innovation-led structure.
Mandate
The firm must pivot towards high-value complex generics and niche oncology portfolios to break out of current stagnant growth cycles.
The firm must pivot towards high-value complex generics and niche oncology portfolios to break out of current stagnant growth cycles.
Financials
Revenue FY25₹1K Cr
PAT FY25₹78 Cr
Rev CAGR 5Y4.1%
OPM15.6%
NPM6.1%
ROE3.3%
ROCE7.6%
P/E27.7
Fwd P/E17.5
P/B2.5
D/E24.3
Mkt Cap₹7K Cr
Promoter56.7%
Institutional10.9%
Similar Culture
Could You Lead Shilpa Medicare?
Take the Genome Benchmark →